Literature DB >> 23871484

The cardiac ryanodine receptor N-terminal region contains an anion binding site that is targeted by disease mutations.

Lynn Kimlicka1, Ching-Chieh Tung, Anna-Carin Cecilia Carlsson, Paolo Antonio Lobo, Zhiguang Yuchi, Filip Van Petegem.   

Abstract

Ryanodine receptors (RyRs) are calcium release channels located in the membrane of the endoplasmic and sarcoplasmic reticulum and play a major role in muscle excitation-contraction coupling. The cardiac isoform (RyR2) is the target for >150 mutations that cause catecholaminergic polymorphic ventricular tachycardia (CPVT) and other conditions. Here, we present the crystal structure of the N-terminal region of RyR2 (1-547), an area encompassing 29 distinct disease mutations. The protein folds up in three individual domains, which are held together via a central chloride anion that shields repulsive positive charges. Several disease mutant versions of the construct drastically destabilize the protein. The R420Q disease mutant causes CPVT and ablates chloride binding. The mutation results in reorientations of the first two domains relative to the third domain. These conformational changes likely activate the channel by destabilizing intersubunit interactions that are disrupted upon channel opening.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23871484     DOI: 10.1016/j.str.2013.06.012

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  24 in total

1.  The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry.

Authors:  Thomas M Roston; Zhiguang Yuchi; Prince J Kannankeril; Julie Hathaway; Jeffrey M Vinocur; Susan P Etheridge; James E Potts; Kathleen R Maginot; Jack C Salerno; Mitchell I Cohen; Robert M Hamilton; Andreas Pflaumer; Saira Mohammed; Lynn Kimlicka; Ronald J Kanter; Martin J LaPage; Kathryn K Collins; Roman A Gebauer; Joel D Temple; Anjan S Batra; Christopher Erickson; Maria Miszczak-Knecht; Peter Kubuš; Yaniv Bar-Cohen; Michal Kantoch; Vincent C Thomas; Gabriele Hessling; Chris Anderson; Ming-Lon Young; Sally H J Choi; Michel Cabrera Ortega; Yung R Lau; Christopher L Johnsrude; Anne Fournier; Filip Van Petegem; Shubhayan Sanatani
Journal:  Europace       Date:  2018-03-01       Impact factor: 5.214

2.  Effective cascade screening through identification of a mutation in RYR2 in a large family with a history of sudden death.

Authors:  Claire Bailey; Edward Blair; Clifford Garratt; William G Newman
Journal:  J Cardiol Cases       Date:  2015-10-01

3.  RyR2R420Q catecholaminergic polymorphic ventricular tachycardia mutation induces bradycardia by disturbing the coupled clock pacemaker mechanism.

Authors:  Yue Yi Wang; Pietro Mesirca; Elena Marqués-Sulé; Alexandra Zahradnikova; Olivier Villejoubert; Pilar D'Ocon; Cristina Ruiz; Diana Domingo; Esther Zorio; Matteo E Mangoni; Jean-Pierre Benitah; Ana María Gómez
Journal:  JCI Insight       Date:  2017-04-20

4.  Reclassification of Variants of Uncertain Significance in Children with Inherited Arrhythmia Syndromes is Predicted by Clinical Factors.

Authors:  Jeffrey S Bennett; Madison Bernhardt; Kim L McBride; Shalini C Reshmi; Erik Zmuda; Naomi J Kertesz; Vidu Garg; Sara Fitzgerald-Butt; Anna N Kamp
Journal:  Pediatr Cardiol       Date:  2019-09-18       Impact factor: 1.655

5.  Roles of the NH2-terminal domains of cardiac ryanodine receptor in Ca2+ release activation and termination.

Authors:  Yingjie Liu; Bo Sun; Zhichao Xiao; Ruiwu Wang; Wenting Guo; Joe Z Zhang; Tao Mi; Yundi Wang; Peter P Jones; Filip Van Petegem; S R Wayne Chen
Journal:  J Biol Chem       Date:  2015-01-27       Impact factor: 5.157

6.  Cardiac hypertrophy and arrhythmia in mice induced by a mutation in ryanodine receptor 2.

Authors:  Francisco J Alvarado; J Martijn Bos; Zhiguang Yuchi; Carmen R Valdivia; Jonathan J Hernández; Yan-Ting Zhao; Dawn S Henderlong; Yan Chen; Talia R Booher; Cherisse A Marcou; Filip Van Petegem; Michael J Ackerman; Héctor H Valdivia
Journal:  JCI Insight       Date:  2019-03-05

7.  A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.

Authors:  Carlos A Ibarra Moreno; Natalia Kraeva; Elena Zvaritch; Lourdes Figueroa; Eduardo Rios; Leslie Biesecker; Filip Van Petegem; Philip M Hopkins; Sheila Riazi
Journal:  Br J Anaesth       Date:  2020-08-27       Impact factor: 9.166

8.  A chloride channel blocker prevents the suppression by inorganic phosphate of the cytosolic calcium signals that control muscle contraction.

Authors:  Juan J Ferreira; Germán Pequera; Bradley S Launikonis; Eduardo Ríos; Gustavo Brum
Journal:  J Physiol       Date:  2020-10-19       Impact factor: 5.182

9.  Calcium signaling consequences of RyR2 mutations associated with CPVT1 introduced via CRISPR/Cas9 gene editing in human-induced pluripotent stem cell-derived cardiomyocytes: Comparison of RyR2-R420Q, F2483I, and Q4201R.

Authors:  Xiao-Hua Zhang; Hua Wei; Yanli Xia; Martin Morad
Journal:  Heart Rhythm       Date:  2020-09-12       Impact factor: 6.343

10.  Impaired Binding to Junctophilin-2 and Nanostructural Alteration in CPVT Mutation.

Authors:  Liheng Yin; Alexandra Zahradnikova; Riccardo Rizzetto; Josefina Ramos-Franco; Esther Zorio; Spyros Zissimopoulos; Feliciano Protasi; Jean-Pierre Benitah; Simona Boncompagni; Camille Rabesahala de Meritens; Yadan Zhang; Pierre Joanne; Elena Marqués-Sulé; Yuriana Aguilar-Sánchez; Miguel Fernández-Tenorio; Olivier Villejoubert; Linwei Li; Yue Yi Wang; Philippe Mateo; Valérie Nicolas; Pascale Gerbaud; F Anthony Lai; Romain Perrier; Julio L Álvarez; Ernst Niggli; Héctor H Valdivia; Carmen R Valdivia; Ana M Gómez
Journal:  Circ Res       Date:  2021-06-11       Impact factor: 23.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.